First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Arrowhead Pharmaceuticals, Inc.

    ARWR · 10 developments mapped · last assessed 2026-09-25

    Market Ontology has mapped 10 macro, policy, and market developments to Arrowhead Pharmaceuticals, Inc. since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ARWR yet, so no modelled value is shown. The ARWR valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ARWR on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ARWR. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

      Increased investor confidence in RNA-based therapeutics and the broader biotech funding environment. ADARx's focus on RNA-targeting therapies could draw attention to similar companies.

      · Moves peer group valuation multiples, investor perception of technology risk

    • Open question

      Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR

      Potential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.

      · Moves probability of success, peak sales estimates, cost of capital

    What changed, by assumption

    Probability of success
    • 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
    • 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
    Market share projections
    • 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
    Peer group valuation multiples
    • 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
    Investor sentiment towards sirna platform technology
    • 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
    Investor sentiment towards advanced therapies for rare/autoimmune diseases
    • 2026-09-24Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per sharemixed3-12m0.30
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqBullish1-3m0.30
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Sharewatch1-3m0.20
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per sharewatch1-3m0.30
    2026-09-24Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026watch3-12m0.30
    2026-09-16Acumen Pharmaceuticals Projects Cash Runway into Early 2027watch3-12m0.10
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRwatch1-5y0.40
    2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicswatch1-5y0.40
    2026-09-01Valion Bio, Inc. Follow-On — $7.7Mwatch3-12m0.10
    2026-08-19Vogenx, Inc. IPO — $12Mwatch3-12m0.20